Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Retained Earnings (2016 - 2025)

Traws Pharma (TRAW) has disclosed Retained Earnings for 14 consecutive years, with $6000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Retained Earnings rose 100.0% to $6000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $6000.0, a 100.0% increase, with the full-year FY2024 number at -$649.2 million, down 34.5% from a year prior.
  • Retained Earnings was $6000.0 for Q3 2025 at Traws Pharma, down from $9000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $9000.0 in Q2 2025 to a low of -$649.2 million in Q4 2024.
  • A 5-year average of -$315.3 million and a median of -$444.7 million in 2021 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: crashed 2181175.0% in 2024, then skyrocketed 100.0% in 2025.
  • Traws Pharma's Retained Earnings stood at -$444.7 million in 2021, then fell by 4.26% to -$463.7 million in 2022, then decreased by 4.09% to -$482.6 million in 2023, then tumbled by 34.5% to -$649.2 million in 2024, then surged by 100.0% to $6000.0 in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Retained Earnings are $6000.0 (Q3 2025), $9000.0 (Q2 2025), and -$19000.0 (Q1 2025).